Advertisement

Related Videos

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Amit Sanyal, MD: A Clinician’s Perspective

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Deborah Collyar: What's In It for Patients?

Advertisement

Advertisement




Aug
17
Today In Oncology
AI Model Predicts TP53 Status Tumor Type and Survival From Routine HE Slides
Darovasertib Plus Crizotinib May Set New First-Line Standard in HLA-A2–Negative Metastatic Uveal Melanoma
What Is the Optimal PSA to Determine Prostate Cancer Treatment Efficacy
Can Newborn Genetic Testing Identify Cancer Predisposition Genes
FDA Approves CELMoD Combination Regimen for Pretreated Multiple Myeloma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo